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Abstract
Background: Intravenous injection of mice with attenuated Plasmodium berghei sporozoites induces sterile
immunity to challenge with viable sporozoites. Non-intravenous routes have been reported to yield poor
immunity. Because intravenous immunization has been considered to be unacceptable for large scale vaccination
of humans, assessment was made of the results of intradermal immunization of mice with Plasmodium yoelii, a
rodent malaria parasite whose infectivity resembles that of human malaria.
Methods: Mice were immunized with two injections of isolated, radiation-attenuated P. yoelii sporozoites, either by
intravenous (IV) or intradermal (ID) inoculation. In an attempt to enhance protective immunogenicity of IDinjections, one group of experimental mice received topical application of an adjuvant, Imiquimod, while another
group had their injections accompanied by local “tape-stripping” of the skin, a procedure known to disrupt the
stratum corneum and activate local immunocytes. Challenge of immunized and non-immunized control mice was
by bite of sporozoite-infected mosquitoes. Degree of protection among the various groups of mice was
determined by microscopic examination of stained blood smears. Statistical significance of protection was
determined by a one-way ANOVA followed by Tukey’s post hoc test.
Results: Two intravenous immunizations produced 94% protection to mosquito bite challenge; intradermal
immunization produced 78% protection, while intradermal immunization accompanied by “tape-stripping”
produced 94% protection. There were no statistically significant differences in degree of protective immunity
between immunizations done by intravenous versus intradermal injection.
Conclusions: The use of a sub-microlitre syringe for intradermal injections yielded excellent protective immunity.
ID-immunization with large numbers of radiation-attenuated P. yoelii sporozoites led to levels of protective
immunity comparable to those achieved by IV-immunization. It remains to be determined whether an adjuvant
treatment can be found to substantially reduce the numbers of attenuated sporozoites required to achieve a
strong protective immunity with as few doses as possible for possible extension to immunization of humans.

Background
In spite of the huge global morbidity and mortality
inflicted by malaria, an effective and practical vaccine
against this disease has not yet been achieved. Early studies on immunization against sporozoite-induced rodent
malaria resulted in close to 100% protection when mice
were immunized with Plasmodium berghei sporozoites
irradiated to sufficient levels and the immunized mice
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were subsequently challenged with non-irradiated sporozoites [1,2].
Nevertheless, immunization with attenuated P. berghei
sporozoites via routes other than intravenous (IV) was
found to be far less protective. Thus, even after five
immunizations, mice immunized by intramuscular (IM),
intraperitoneal (IP) or intradermal (ID) routes were protected only 32%, 26% and 24%, respectively, in contrast
to 95% protection after IV immunization [3]. In another
P. berghei study done with similar protocols, IM immunization resulted in only 11% protection, although addition of albumin to the immunizing inoculum raised this
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to 42%; in contrast, IV immunization yielded 100% protection [4].
Because sporozoite suspensions used for immunization
were heavily contaminated with microorganisms and
mosquito components, it was clear that such immunization trials by IV injection could not be directly extended
to humans. An alternate approach, however, allowed irradiated mosquitoes to directly inoculate attenuated sporozoites into hosts, the mosquitoes thereby acting as
vehicles of immunization. This approach was first established with rodent malaria [5] and then extended to the
first successful human vaccination trial against P falciparum malaria [6]. A compendium of subsequent human
vaccination trials with this approach showed that when
sufficient numbers of mosquitoes were used for immunization, greater than 90% of volunteers were completely
protected against challenge by bite of infected mosquitoes [7,8]. Recent progress by this group, under the auspices of the biopharmaceutical company Sanaria, has
permitted the raising of large numbers of mosquitoes
infected with Plasmodium falciparum sporozoites, the
purification of these sporozoites sufficient to render
them acceptable for human vaccination, and the successful freeze-preservation of the attenuated sporozoites.
Trials are currently underway to attempt to vaccinate
humans by syringe injection of these sporozoites [9,10].
A central question for any human trials relates to an
appropriate route of immunization. It had long been
assumed that most sporozoites injected by mosquitoes
rapidly reach the blood, after which they travel to the
liver for further development. Thus, there was a supposition that sporozoite inoculation by mosquitoes mimicked
IV inoculation of sporozoites by syringe. But studies have
shown that most if not all mosquito-injected sporozoites
are deposited into avascular portions of the skin and subcutaneous tissues and that sporozoites then use gliding
motility to reach blood vessels to travel to the liver
[11,12], or enter lymph vessels to travel to local draining
lymph nodes [12]. This has led to the possibility that
inoculation of isolated sporozoites directly into the skin
by syringe might successfully replicate the recognized
successful approach of allowing mosquitoes to inoculate
attenuated sporozoites into skin.
Accordingly, the Plasmodium yoelii rodent malaria
system was used to explore this approach and investigate ways of further enhancing the protective immunogenicity of ID-injected, attenuated sporozoites. The
P. yoelii system is far superior to the P. berghei system
in the infectivity of sporozoites, appearing to be similar
in that respect to the human malarias. Indeed, others
have contended that “the P. yoelii system has accurately
predicted the success or failure of every approach to
malaria vaccination that has been tested in humans”
[13]. A recent publication reported that it took at least
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four ID immunizations with a total of 6,000 P. yoelii
sporozoites to equal the protective immunity that could
be accomplished with only three doses and a total of
only 2,250 sporozoites administered IV [14]. Because of
the practical value of achieving protective immunity
with fewer doses of sporozoites, the current study tested
whether a substantially higher number of sporozoites
given in only two doses ID might result in protection
equivalent to that obtained with IV immunization.
The main goal was to assess the protective immunogenicity of attenuated P. yoelii sporozoites injected by
syringe into the skin. ID immunization with P. yoelii
sporozoites was found to give far better protection than
had been observed in previous attempts using non-IV
routes of administration to immunize with P. berghei
sporozoites [3,4]. Furthermore, administering larger
numbers of P. yoelii sporozoites ID was able to give a
degree of protective immunity equivalent to what had
been reported for ID immunization with twice the number of immunizing doses [14].
Finally, because many sporozoites injected by mosquitoes remain in the skin and either deteriorate [11] or
differentiate [15] and because such sporozoites may be
involved in induction of the immune response [16], two
methods were tested to possibly enhance the immune
response with adjuvants in conjunction with IDadministration of sporozoites; a) topical application of
the toll-like receptor (TLR) agonist Imiquimod, as previously done for immunization studies using sub-unit
vaccines against malaria [17], b) “tape-stripping” (TS), a
procedure known to disrupt the stratum corneum and
enhance the immunogenicity of ID-injected antigens
[18]. All ID-injection procedures were found to lead to
levels of protection not significantly different from that
which had been observed after IV immunization.

Methods
Host-parasite system

Plasmodium yoelii sporozoites (strain 17XNL) were produced in Anopheles stephensi mosquitoes. Standard protocols were used for infecting and maintaining
mosquitoes [19], which were infected by feeding upon
gametocyte-carrying 6-8 wk-old Swiss-Webster mice
(Taconic Farms Inc., Germantown, NY). Protocols for
maintenance and use of experimental animals were
approved by the Institutional Animal Care and Use
Committee at New York University School of Medicine,
whose animal facility is accredited by the Association
for Assessment and Accreditation of Laboratory Animal
Care International (Rockville, MD).
Isolation of sporozoites for immunization

Sporozoites for immunization were isolated from mosquitoes 18 days after the mosquitoes had received an

Voza et al. Malaria Journal 2010, 9:362
http://www.malariajournal.com/content/9/1/362

infective blood meal. To obtain sporozoites, mosquitoes
were anesthetized on ice, then washed with 70% ethanol,
followed by RPMI medium 1640 (Gibco BRL, Grand
Island, NY). Salivary glands were dissected out and triturated in RPMI medium supplemented with 2% mouse
serum albumin, after which the freed sporozoites were
counted in a haemacytometer and diluted to appropriate
concentrations for immunization.
Immunization and challenge protocols

Sporozoites were irradiated within a gamma irradiator
(MDS Nordion Gammacell® 1000 Elite) to a central dose
of ± 12,049 cGy and a minimum dose of ± 10,266 cGy.
Mice (BALB/c females from Taconic Farms Inc., Germantown, NY) were 6 wk old at the initiation of each
experiment (n = 6/group for each experiment). For
immunization, they received an initial injection of
60,000 irradiated sporozoites, with a subsequent booster
injection of 30,000 irradiated sporozoites 15 days afterwards. Intravenous (IV) injections into a tail vein were
given in a volume of 200 μl per mouse. For intradermal
(ID) immunizations, a portion of flank skin was shaved
and injections were given with a Nanofil TM SubMicroliter syringe with a 33G flexifil beveled tip (World
Precision Instruments, Sarasota, Florida, USA) in two
adjacent sites in a volume of 5 μl per site.
Parallel ID immunizations were given to groups of
mice that received topical treatment with an adjuvant or
an adjuvant procedure. For topical treatment with Imiquimod (obtained as a 5% cream containing 12.5 mg/ml
of Imiquimod [Aldara; 3 M, St. Paul, MN]), anesthetized
mice were treated with approximately 25 μl (1.25 mg of
imiquimod) [17]. It was applied by rubbing into the
shaved skin area 4 h after ID immunization, then reapplied 1 and 2 days after immunization. This process was
repeated for the booster immunization.
For assessment of the adjuvant effect of TS, a small
area of the shaved flank skin of anesthetized mice was
treated by applying and pulling off a strip of adhesive
tape (Scotch Brand 3 M Magic tape) 10 times. A fresh
piece of tape was used for each of the 10 strippings.
This procedure is known to disrupt the stratum corneum [18], and resulted in local erythema and inflammation typical of what has been demonstrated in
previous studies with tape-stripped mice [18]. Tapestripping was done 30 min after ID immunization with
sporozoites and was repeated for the booster
immunization.
Mice were anesthetized and then challenged by mosquito bite 15 days after the second immunization. Parallel challenges were done on non-immunized control
mice from the same cohort. For each mouse, five different infected mosquitoes from the same cohort were
allowed to probe and feed for 5 min. Thin blood smears
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were prepared from drops of tail blood up to 14 days
after challenge and stained with Giemsa.
Statistics

The percentages of mice that developed parasitemia and
the pre-patent periods of those that developed parasitemia after challenge by mosquito bite were recorded.
Comparisons were made between the percentages of
mice infected after the various immunization regimens
(IV, ID, ID+imiquimod, ID + TS) versus the percentage
of non-immunized controls that were infected. To do
these comparisons, all data were transformed using the
following equation y = arcsin[√(y/100)], where y represents percentage of infection. Gaussian distribution of
transformed data was then confirmed using the Kolmogorov-Smirnov normality test. A one-way ANOVA followed by Tukey’s post hoc test was then used to
compare the differences between groups of mice. The
analyses were performed using GraphPad Prism Version
5 software (San Diego, California).

Results
Challenges by mosquito injection of sporozoites

The results of three independent experiments are shown
in Table 1. Mice immunized by two IV injections of
sporozoites and challenged by mosquito bite had an
overall protection of 94%, compared with non-immunized controls. Mice immunized by ID injections had an
overall protection of 78%. When attempts were made to
enhance ID immunizations by adjuvant treatments,
treatment with Imiquimod resulted in 67% protection,
Table 1 Effect of immunization protocols with
Plasmodium yoelii attenuated sporozoites on
development of protective immunity
Route of
Immunization

Exp’t 1

Non-Immunized
Controls

6/6 (0%)a 6/6 (0%)
6/6 (0%)
18/18
[PP = 3.0] [PP = 3.3] [PP = 3.3] (0%)
b
[PP = 3.3]

Exp’t 3

Total

IVc-Immunized

0/6
(100%)

IDd-Immunized

3/6 (50%) 1/6 (83%) 0/6
[PP = 5.0] [PP = 9.0] (100%)

ID-Immunized
+ Imiquimod

1/6 (83%) 1/6 (83%) 4/6 (33%) 6/18
[PP = 5.0] [PP = 4.0] [PP = 4.2] (67%)
[PP = 4.3]

ID-Immunized
+ Tape Stripping
a

Exp’t 2

0/6
(100%)

1/6 (83%) 0/6
[PP = 4 0] (100%)

1/6 (83%) 1/18
[PP = 6.0] (94%)
[PP = 6.0]

0/6
(100%)

4/18
(78%)
[PP = 6.0]

1/18
(94%)
[PP = 4.0]

Results of challenge by mosquito injection of sporozoites. # of mice with
blood infection/# challenged; (% protected in parentheses)
b
[Mean prepatent period in days for positive mice]
c
IV = intravenous
d
ID = intradermal
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while treatment by TS gave 94% protection. In spite of
the fact that the percentage of mice protected after ID
immunization with TS was the same as the percentage
protected after IV immunization, it was not possible to
demonstrate that these were significantly better
than protection observed after ID immunization alone
(P > 0.05).

Discussion
A proof of concept study done more than 35 years ago
showed the possibility of immunizing humans against
malaria by irradiating infected mosquitoes and allowing
them to inject attenuated P. falciparum sporozoites into
volunteers [6]. In subsequent human trials with sporozoite vaccination via mosquito injection, greater than
90% of volunteers were protected against challenge by
bite of irradiated, infected mosquitoes [7,8]. Nevertheless, the impracticality of immunization by mosquito
bite was obvious. A more recently proposed approach is
based on syringe injection of purified and freeze-preserved, attenuated P. falciparum sporozoites isolated
from mosquito salivary glands [9,10].
However, early studies with P. berghei sporozoites suggested that immunization by syringe injection of sporozoite suspensions was not very effective unless the
sporozoite suspensions were administered IV. As this is
not a feasible mode of administration for large scale
immunization of humans, more suitable modes of syringe injection of sporozoites were revisited with another
species of rodent malaria, P. yoelii. The rationale for this
is that far fewer P. yoelii than P. berghei sporozoites are
required, either to infect [20,21] or to protectively
immunize [22] mice.
Results for three experiments in the present study
showed an overall 94% protection for mice immunized
IV vs. 78% for ID immunization after only two immunizations. An initial pilot experiment using three immunizations for this study had yielded 100% protection after
IV immunization, compared to 83% protection with ID
immunization (data not shown). It has been reported
that two IV doses of irradiated P. yoelii sporozoites rarely
provides solid protection, while three IV doses does so
consistently [22,23]. Thus, to better discriminate between
the effects of various types of immunization protocols
with and without adjuvant treatments, subsequent immunization experiments were performed with only two
immunizations, as presented in this paper. It was anticipated that such suboptimal immunization might better
differentiate the effects of adjuvant treatments. Furthermore, it has been noted that a goal for eventual human
vaccination is to achieve high-level protection with the
fewest numbers of doses of vaccine [10].
When adjuvant treatments in conjunction with the ID
immunizations were evaluated, it was found that topical
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application of Imiquimod resulted in an overall protection rate of 67%, whereas TS gave 94% protection. IV
immunization is the generally accepted “gold standard”
for protection achieved with attenuated sporozoites.
Although TS in conjunction with ID immunization
yielded the same degree of protection as IV-immunization, it was not possible to show statistically that the
protection induced by ID immunization together with
TS was significantly better than ID immunization alone.
Imiquimod is a TLR agonist that stimulates local immunocytes, including dermal dendritic cells, when topically
applied [24]. It has been successfully used as an adjuvant
to increase protective immunity against Leishmania
major in BALB/c mice [25] and to enhance immunogenicity of a peptide-based vaccine against Plasmodium
sporozoites [17]. However, topically applied Imiquimod
showed no enhancing effects when used in association
with ID-injection of radiation attenuated sporozoites.
Tape stripping together with ID-injection of sporozoites, on the other hand, protected the same percentage
of mice as observed after IV immunization. Tape stripping consists of partially removing the stratum corneum,
the outermost layer of the epidermis, by use of adhesive
strips applied to the skin and then removed [18]. This
procedure had been shown to enhance the immune
response to an ID-injected protein antigen in the tapestripped area [18] and [26]. It is known to result in local
inflammation, with movement of antigen-presenting
cells into affected regions and enhancement of immune
surveillance [26], as well as induction of TLR-9 mRNA
[27]. The rationale for using TS was based on previous
observations that mosquitoes inject sporozoites into
avascular portions of skin and subcutaneous tissues and
that many sporozoites remain in the skin and become
fragmented within several hours [11] and [28]. Furthermore, it has been shown that an anti-sporozoite
response originates early in lymphoid tissues linked to
cutaneous infection sites and it was suggested that this
originates with internalization of sporozoite antigen by
immature dendritic cells in the skin [16]. The current
study hypothesized that the effects of TS might enhance
interactions between immunocytes and sporozoites
deposited in the skin.
The 78% protection reported here after simple ID
administration of radiation-attenuated P. yoelii sporozoites with only two immunizations is substantially
higher than any non-IV route of immunization previously reported with P. berghei sporozoites. A prior
study by others had also reported good protective
results after non-IV immunization with attenuated P.
yoelii sporozoites [14]. Nevertheless, that study had
reported that four doses of P. yoelii sporozoites given ID
or SC were required to achieve protection similar to
what was achieved with three doses of fewer sporozoites
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administered IV. Those results, as well as the ones
reported here, are encouraging because it has been
argued that “experiments using attenuated P. yoelii sporozoite vaccines have consistently paralleled or predicted
results in humans exposed to P. falciparum sporozoites”
[22]. Because of the practical operational value of
achieving protective immunity with as few doses of
sporozoites as possible, the present study tested whether
only two ID doses given with a relatively high number
of sporozoites might result in protection comparable to
that obtained with IV immunization. The current study
now shows that this is the case with P. yoelii malaria.
When two immunizing doses with large numbers of
sporozoites were used, there were no significant differences between results obtained with IV-versus IDimmunization. Indeed, ID-immunization accompanied
by TS gave the same degree of protection obtained with
the IV immunization “gold standard. These results are
in accord with a retrospective analysis showing that
immunization of humans with P. falciparum sporozoites
injected by irradiated mosquitoes was most effective
when large numbers of immunizing mosquito bites were
used to introduce larger numbers of attenuated sporozoites into the vaccinees. Immunization with greater
than 1,000 such bites led to total protection in 33 of 35
challenges, with protection lasting up to 10.5 months
[9]. It remains to be determined whether an adjuvant
treatment in conjunction with ID-immunization by syringe can be found to substantially reduce the numbers
of attenuated sporozoites required to achieve a strong
protective immunity with as few immunizing doses as
possible.

Conclusion
ID-immunization with large numbers of radiationattenuated P. yoelii sporozoites with as few as two
immunizing doses leads to levels of protective immunity
comparable to those achieved by IV-immunization.
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